Abstract:BackgroundEsophageal adenocarcinoma (EAC) often presents at a late, incurable stage, and mortality has increased substantially, due to an increase in incidence of EAC arising out of Barrett’s esophagus. When diagnosed early, however, the combination of surgery and adjuvant therapies is associated with high cure rates. Metabolomics provides a means for non- invasive screening of early tumor-associated perturbations in cellular metabolism.MethodsUrine samples from patients with esophageal carcinoma (n = 44), Barrett’s esophagus (n = 31), and healthy controls (n = 75) were examined using 1H-NMR spectroscopy. Targeted profiling of spectra using Chenomx software permitted quantification of 66 distinct metabolites. Unsupervised (principal component analysis) and supervised (orthogonal partial least-squares discriminant analysis OPLS-DA) multivariate pattern recognition techniques were applied to discriminate between samples using SIMCA-P+ software. Model specificity was also confirmed through comparison with a pancreatic cancer cohort (n = 32).ResultsClear distinctions between esophageal cancer, Barrett’s esophagus and healthy controls were noted when OPLS-DA was applied. Model validity was confirmed using two established methods of internal validation, cross-validation and response permutation. Sensitivity and specificity of the multivariate OPLS-DA models were summarized using a receiver operating characteristic curve analysis and revealed excellent predictive power (area under the curve = 0.9810 and 0.9627 for esophageal cancer and Barrett’s esophagus, respectively). The metabolite expression profiles of esophageal cancer and pancreatic cancer were also clearly distinguishable with an area under the receiver operating characteristics curve (AUROC) = 0.8954.ConclusionsUrinary metabolomics identified discrete metabolic signatures that clearly distinguished both Barrett’s esophagus and esophageal cancer from controls. The metabolite expression profile of esophageal cancer was also discrete from its precursor lesion, Barrett’s esophagus. The cancer-specific nature of this profile was confirmed through comparison with pancreatic cancer. These preliminary results suggest that urinary metabolomics may have a future potential role in non-invasive screening in these conditions.

Urinary 1H-NMR Metabolic Signature in Subjects Undergoing Colonoscopy for Colon Cancer Diagnosis

Urinary metabonomic study on colorectal cancer.

Distinct urinary metabolic profile of human colorectal cancer.

Metabolic profiling analysis for clinical urine of colorectal cancer

Metabolomic Comparison of Patients With Colorectal Cancer at Different Anticancer Treatment Stages

Distinct Urinary Metabolic Biomarkers of Human Colorectal Cancer

Fecal metabolomic profiles: A comparative study of patients with colorectal cancer vs adenomatous polyps

Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS.

Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry.

Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer

NMR‐based metabolomics combined with metabolic pathway analysis reveals metabolic heterogeneity of colorectal cancer tissue at different anatomical locations and stages

Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery.

Metabolic Profiling of Human Colorectal Cancer Using High Resolution 1H Nuclear Magnetic Resonance Spectroscopy

Ultra-High Performance Liquid Chromatography–Mass Spectrometry for the Metabolomic Analysis of Urine in Colorectal Cancer

LC–MS-based serum metabolomics analysis for the screening and monitoring of colorectal cancer

Metabonomics Identifies Serum Metabolite Markers of Colorectal Cancer

¹H NMR-based metabolic profiling of human rectal cancer tissue

Urinary metabolomic signature of esophageal cancer and Barrett’s esophagus

Metabolomics Analysis in Serum from Patients with Colorectal Polyp and Colorectal Cancer by 1H-NMR Spectrometry

Tissue metabolic profiling reveals major metabolic alteration in colorectal cancer

Untargeted GC-MS-Based Metabolomics for Early Detection of Colorectal Cancer